Marbodin (Memantine)

Memantine acts as a non‑competitive antagonist at the NMDA receptor, blocking excessive calcium influx that occurs during prolonged glutamate activation. This reduces excitotoxic neuronal injury while allowing normal synaptic transmission to continue.

The dose of memantine is individualized by the prescribing clinician based on the patient’s condition, renal function, and tolerability. Dosage adjustments are made according to professional guidelines and the patient’s response.

Safety data for memantine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Marbodin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability.

Marbodin is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include seizures, hallucinations or psychosis, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, and suicidal thoughts. Patients should be monitored closely for any of these events.

Memantine is contraindicated in patients with known hypersensitivity to the drug. Caution is advised for individuals with uncontrolled seizures, severe renal impairment, or those taking other NMDA antagonists, as combined use may increase toxicity.